JP2010519235A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010519235A5 JP2010519235A5 JP2009550246A JP2009550246A JP2010519235A5 JP 2010519235 A5 JP2010519235 A5 JP 2010519235A5 JP 2009550246 A JP2009550246 A JP 2009550246A JP 2009550246 A JP2009550246 A JP 2009550246A JP 2010519235 A5 JP2010519235 A5 JP 2010519235A5
- Authority
- JP
- Japan
- Prior art keywords
- riboflavin
- mthfr
- polymorphism
- blood pressure
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 28
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims 14
- 229960002477 riboflavin Drugs 0.000 claims 14
- 239000002151 riboflavin Substances 0.000 claims 14
- 235000019192 riboflavin Nutrition 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 9
- 101000587058 Homo sapiens Methylenetetrahydrofolate reductase Proteins 0.000 claims 6
- 102100029684 Methylenetetrahydrofolate reductase Human genes 0.000 claims 6
- 229940030600 antihypertensive agent Drugs 0.000 claims 6
- 239000002220 antihypertensive agent Substances 0.000 claims 6
- 230000036772 blood pressure Effects 0.000 claims 6
- 239000002160 alpha blocker Substances 0.000 claims 4
- 239000002876 beta blocker Substances 0.000 claims 4
- 229940097320 beta blocking agent Drugs 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 229940127557 pharmaceutical product Drugs 0.000 claims 3
- 239000005541 ACE inhibitor Substances 0.000 claims 2
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims 2
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 claims 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 239000002934 diuretic Substances 0.000 claims 2
- 229960002003 hydrochlorothiazide Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 235000016709 nutrition Nutrition 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 2
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical group O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 claims 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical group CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims 1
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 claims 1
- RZPZLFIUFMNCLY-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol Chemical compound OC(=O)\C=C\C(O)=O.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 RZPZLFIUFMNCLY-WLHGVMLRSA-N 0.000 claims 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 claims 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims 1
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 1
- 239000002051 C09CA08 - Olmesartan medoxomil Substances 0.000 claims 1
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 claims 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims 1
- 108010061435 Enalapril Proteins 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- 108010007859 Lisinopril Proteins 0.000 claims 1
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 claims 1
- UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 claims 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims 1
- 229960000528 amlodipine Drugs 0.000 claims 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims 1
- 229960002274 atenolol Drugs 0.000 claims 1
- 229960004530 benazepril Drugs 0.000 claims 1
- 229960003515 bendroflumethiazide Drugs 0.000 claims 1
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 claims 1
- 229960005400 bisoprolol fumarate Drugs 0.000 claims 1
- 229960004349 candesartan cilexetil Drugs 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- 229960004195 carvedilol Drugs 0.000 claims 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical group COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 claims 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 claims 1
- 229960005025 cilazapril Drugs 0.000 claims 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 claims 1
- 229960002896 clonidine Drugs 0.000 claims 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims 1
- 229960004166 diltiazem Drugs 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 claims 1
- 229960001389 doxazosin Drugs 0.000 claims 1
- 229960000309 enalapril maleate Drugs 0.000 claims 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 claims 1
- 229960002198 irbesartan Drugs 0.000 claims 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 1
- 229960001632 labetalol Drugs 0.000 claims 1
- 229960002394 lisinopril Drugs 0.000 claims 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims 1
- 229960004773 losartan Drugs 0.000 claims 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 1
- 229960001300 metoprolol tartrate Drugs 0.000 claims 1
- 229960000619 nebivolol Drugs 0.000 claims 1
- 229960001597 nifedipine Drugs 0.000 claims 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical group COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- 229960001199 olmesartan medoxomil Drugs 0.000 claims 1
- 229960002582 perindopril Drugs 0.000 claims 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims 1
- 229960001085 piretanide Drugs 0.000 claims 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims 1
- 229960001289 prazosin Drugs 0.000 claims 1
- 229960001455 quinapril Drugs 0.000 claims 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical group C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims 1
- 229960003401 ramipril Drugs 0.000 claims 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims 1
- 229960005187 telmisartan Drugs 0.000 claims 1
- WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 claims 1
- 229960002051 trandolapril Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 229960004699 valsartan Drugs 0.000 claims 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 1
- 229960001722 verapamil Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0703514.0A GB0703514D0 (en) | 2007-02-23 | 2007-02-23 | Use of riboflavin |
| GB0703514.0 | 2007-02-23 | ||
| PCT/EP2008/001437 WO2008101724A1 (en) | 2007-02-23 | 2008-02-22 | Use of riboflavin in the treatment of hypertension |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010519235A JP2010519235A (ja) | 2010-06-03 |
| JP2010519235A5 true JP2010519235A5 (https=) | 2011-03-31 |
| JP5577100B2 JP5577100B2 (ja) | 2014-08-20 |
Family
ID=37945596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009550246A Expired - Fee Related JP5577100B2 (ja) | 2007-02-23 | 2008-02-22 | 高血圧症治療におけるリボフラビンの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100324019A1 (https=) |
| EP (1) | EP2139488B1 (https=) |
| JP (1) | JP5577100B2 (https=) |
| CN (1) | CN101678030B (https=) |
| CA (1) | CA2679217C (https=) |
| EA (1) | EA019281B1 (https=) |
| ES (1) | ES2393144T3 (https=) |
| GB (1) | GB0703514D0 (https=) |
| MX (1) | MX2009009020A (https=) |
| WO (1) | WO2008101724A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX382403B (es) * | 2012-08-16 | 2025-03-13 | Critical Care Diagnostics Inc | Métodos para predecir el riesgo de desarrollar hipertensión. |
| CN103721259A (zh) * | 2014-01-07 | 2014-04-16 | 深圳奥萨医药有限公司 | 血管紧张素ⅱ受体阻断剂/噻嗪类利尿剂/5-甲基四氢叶酸药物组合物 |
| CN109295216A (zh) * | 2018-11-06 | 2019-02-01 | 宁波艾捷康宁生物科技有限公司 | 预测高血压个体化药物药效的snp位点和检测试剂盒 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4264601A (en) * | 1979-06-12 | 1981-04-28 | The Board Of Regents Of The University Of Oklahoma | Antihypertensive agents and their use in treatment of hypertension |
| EP0272336B1 (de) * | 1986-12-18 | 1991-10-23 | Kurt H. Prof. Dr. Bauer | Gegenüber Lichteinfluss stabilisiertes Nifedipin-Konzentrat und Verfahren zu seiner Herstellung |
| US6485959B1 (en) * | 1998-10-07 | 2002-11-26 | Cedars Sinai Medical Center | Cell preconditioning and cryopresevation medium |
| CN1136895C (zh) * | 2001-05-24 | 2004-02-04 | 魏振鸣 | 一种治疗冠心病的药物 |
| WO2006085128A1 (en) * | 2005-02-09 | 2006-08-17 | Wockhardt Limited | Cardiovascular therapeutic combinations |
| US7838526B2 (en) * | 2005-08-05 | 2010-11-23 | Esther Baldinger | Method of treating neurological disorders |
-
2007
- 2007-02-23 GB GBGB0703514.0A patent/GB0703514D0/en not_active Ceased
-
2008
- 2008-02-22 EP EP08715988A patent/EP2139488B1/en not_active Not-in-force
- 2008-02-22 EA EA200901145A patent/EA019281B1/ru not_active IP Right Cessation
- 2008-02-22 ES ES08715988T patent/ES2393144T3/es active Active
- 2008-02-22 CN CN2008800135209A patent/CN101678030B/zh not_active Expired - Fee Related
- 2008-02-22 MX MX2009009020A patent/MX2009009020A/es active IP Right Grant
- 2008-02-22 JP JP2009550246A patent/JP5577100B2/ja not_active Expired - Fee Related
- 2008-02-22 CA CA2679217A patent/CA2679217C/en active Active
- 2008-02-22 WO PCT/EP2008/001437 patent/WO2008101724A1/en not_active Ceased
- 2008-02-22 US US12/528,105 patent/US20100324019A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Barreras et al. | Angiotensin II receptor blockers | |
| FI4076652T3 (fi) | Farmaseuttisesti hyväksyttävä atrasentanin suola käytettäväksi iga-nefropatiaan hoitomenetelmässä | |
| Kirk | Angiotensin-II receptor antagonists: their place in therapy | |
| CN109069507A (zh) | 匹莫苯对于患有由二尖瓣疾病所致的无症状心力衰竭的患者中减小心脏尺寸和/或延迟临床症状的发作的用途 | |
| CN101384257A (zh) | 药物组合 | |
| Jones et al. | Azilsartan medoxomil (Edarbi): the eighth angiotensin II receptor blocker | |
| JP2010519235A5 (https=) | ||
| TW200637546A (en) | Combination therapy | |
| WO2015028972A1 (en) | Pulsatile-release dosage form | |
| Négrier et al. | Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management | |
| US7625940B2 (en) | Method of treating hypertension with a very low dose of chlorthalidone | |
| CN102458401B (zh) | 高血压或正常高值血压的治疗药 | |
| AU2006252210B2 (en) | New association of a sinus node lf current inhibitor and an angiotensin-converting enzyme inhibitor, and pharmaceutical compositions containing it | |
| Tamuno et al. | Drug treatment for hypertension in a tertiary health care facility in Northern Nigeria | |
| Zannad et al. | [PP. 35.03]: SODIUM ZIRCONIUM CYCLOSILICATE FOR TREATMENT OF HYPERKALAEMIA: ANALYSIS OF PATIENTS ON RENIN-ANGIOTENSIN-ALDOSTERONE INHIBITORS (RAASI) FROM THE PHASE 3 HARMONIZE STUDY | |
| ES2332884T3 (es) | Tratamiento de la lipodistrofia con inhibidores del sistema renina angiotensina. | |
| Kaplan | Renin‐Angiotensin System Blockade: Therapeutic Implications Beyond Blood Pressure Control | |
| Llorca et al. | Interactions between ibuprofen and antihypertensive drugs: Incidence and clinical relevance in dental practice | |
| Chen et al. | P-186: Adverse effects and reasons for switch reported by patients on antihypertensive medications | |
| Lisauskienė et al. | Trends and pattern of the utilization of cardiovascular medicines in Lithuania in 2003–2012 | |
| Carboni et al. | Strategies to improve blood pressure control and cardiovascular outcomes in hypertensive patients: medfile | |
| Cranwell-Bruce | Antihypertensives. | |
| Salinitri et al. | Pharmacotherapeutic blood pressure management in a chronic kidney disease patient | |
| Ruilope et al. | 24-hour ambulatory blood-pressure effects of valsartan+ hydrochlorothiazide combinations compared with amlodipine in hypertensive patients at increased cardiovascular risk | |
| CN1753669A (zh) | 中风急性期的高血压治疗 |